PMID- 27681592 OWN - NLM STAT- MEDLINE DCOM- 20170501 LR - 20210610 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 140 IP - 2 DP - 2017 Jan 15 TI - mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. PG - 390-399 LID - 10.1002/ijc.30451 [doi] AB - The mRECIST and dermatologic adverse events (AEs) can be used to assess the patient response to transarterial chemoembolization (TACE) and/or sorafenib for hepatocellular carcinoma (HCC). Here, we aimed to combine the two criteria to stratify the prognosis in patients with unresectable HCC receiving TACE plus sorafenib (TACE-S). In total, 176 consecutive HCC patients treated with TACE-S were enrolled. CT scans and laboratory tests were conducted pretreatment (at baseline, 5-7 days before the TACE-S) and post-treatment (at 1, 2 and 3 months). The radiological response was assessed according to mRECIST. Sorafenib-related AEs were recorded every 2 weeks after oral administration, and patients with dermatologic AEs of Grade 2 or more were defined as dermatologic responders. The earliest time at which mRECIST and dermatologic responses correlated with survival was 2 months after therapy. The mRECIST-dermatologic AE combination assessment stratified patients into three different prognoses; responders on both assessments exhibited the longest median overall survival (OS), followed by responders on one assessment and non-responders on both assessments (30.5, 17.4 and 8.3 months, respectively; p < 0.001). Achieving the highest C-index, the mRECIST-dermatologic AE combination showed better performance in predicting survival than either mRECIST or dermatologic AEs alone. Furthermore, the mRECIST-dermatologic AE combination remained a significant predictor of OS, even when the patients were stratified according to the BCLC stage, ECOG score or alpha-fetoprotein (AFP) value. This study showed that the combination of mRECIST response and dermatologic AEs is superior to either criterion used alone for predicting the survival of HCC patients treated with TACE-S. CI - (c) 2016 UICC. FAU - Wang, Wenjun AU - Wang W AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Bai, Wei AU - Bai W AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Wang, Enxin AU - Wang E AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Zhao, Yan AU - Zhao Y AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Liu, Lei AU - Liu L AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Yang, Man AU - Yang M AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Cai, Hongwei AU - Cai H AD - Information Center, School of Stomatology, Fourth Military Medical University, Xi'an, China. FAU - Xia, Dongdong AU - Xia D AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Niu, Jing AU - Niu J AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Yin, Zhanxin AU - Yin Z AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Zhang, Zhuoli AU - Zhang Z AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. AD - Department of Radiology, Northwestern University, Chicago, IL. FAU - Fan, Daiming AU - Fan D AD - State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Xia, Jielai AU - Xia J AD - Department of Medical Statistics, Fourth Military Medical University, Xi'an, China. FAU - Han, Guohong AU - Han G AD - Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China. LA - eng GR - R01 CA196967/CA/NCI NIH HHS/United States GR - R01 CA209886/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20161017 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (Antineoplastic Agents) RN - 0 (Phenylurea Compounds) RN - 0 (alpha-Fetoproteins) RN - 25X51I8RD4 (Niacinamide) RN - 9ZOQ3TZI87 (Sorafenib) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/*adverse effects/*therapeutic use MH - Carcinoma, Hepatocellular/*drug therapy/pathology MH - Chemoembolization, Therapeutic/methods MH - Combined Modality Therapy/methods MH - Drug-Related Side Effects and Adverse Reactions/*pathology MH - Female MH - Humans MH - Liver Neoplasms/*drug therapy/pathology MH - Male MH - Middle Aged MH - Niacinamide/adverse effects/*analogs & derivatives/therapeutic use MH - Phenylurea Compounds/*adverse effects/*therapeutic use MH - Prognosis MH - Retrospective Studies MH - Sorafenib MH - Treatment Outcome MH - alpha-Fetoproteins/metabolism OTO - NOTNLM OT - dermatologic adverse events OT - hepatocellular carcinoma OT - mRECIST OT - sorafenib OT - transarterial chemoembolization EDAT- 2016/09/30 06:00 MHDA- 2017/05/02 06:00 CRDT- 2016/09/30 06:00 PHST- 2016/08/30 00:00 [received] PHST- 2016/09/15 00:00 [accepted] PHST- 2016/09/30 06:00 [pubmed] PHST- 2017/05/02 06:00 [medline] PHST- 2016/09/30 06:00 [entrez] AID - 10.1002/ijc.30451 [doi] PST - ppublish SO - Int J Cancer. 2017 Jan 15;140(2):390-399. doi: 10.1002/ijc.30451. Epub 2016 Oct 17.